Skip to main content
search
Press Coverage

How biosimulation and virtual trials can bust through clinical trial roadblocks

Publication: Drug Discovery & Development

The article explores how using biosimulation for rare disease drug development can help overcome challenges in traditional clinical trials. Experts from Certara- Drs. Rajesh Krishna and Oxana Iliach, highlight how these technologies can be used to enhance statistical precision, create virtual cohorts, simulate control arms, and optimize trial designs. The discussion also covers policy changes and collaborative frameworks to boost accessibility and development in the rare disease space.

Published: March 14, 2025

Therapeutic area

Rare and Neglected Diseases

Learn more about Rare and Neglected Diseases

Transform your rare disease drug development with Certara’s integrated solutions. From preclinical insights to market access strategies, we provide unparalleled expertise to guide you through every stage of the drug development process.

Learn more

You May Also Like

Rare Oncology Product Launch Playbook: Universal Strategies for Success in the U.S. and Europe
Rare Oncology Product Launch Playbook: Universal Strategies for Success in the U.S. and EuropeWhite Paper

Rare Oncology Product Launch Playbook: Universal Strategies for Success in the U.S. and Europe

Accelerating CMC Success in Rare Disease Drug Development
Accelerating CMC Success in Rare Disease Drug DevelopmentVideo

Accelerating CMC Success in Rare Disease Drug Development

Leveraging Real-World Evidence (RWE) in Rare Disease Drug Development
Leveraging Real-World Evidence (RWE) in Rare Disease Drug DevelopmentVideo

Leveraging Real-World Evidence (RWE) in Rare Disease Drug Development